# Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study

> **NCT05013957** · — · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 32 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DIAGNOSTIC_TEST:** Methylation analysis

## Key facts

- **NCT ID:** NCT05013957
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05013957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05013957, "Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05013957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*